1. Home
  2. VGZ vs VTGN Comparison

VGZ vs VTGN Comparison

Compare VGZ & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$2.65

Market Cap

360.5M

Sector

N/A

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.30

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
VTGN
Founded
1983
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.5M
10.8M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
VGZ
VTGN
Price
$2.65
$0.30
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
★ $3.75
$0.90
AVG Volume (30 Days)
1.8M
★ 18.6M
Earning Date
05-12-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.43
$0.20
52 Week High
$3.13
$5.14

Technical Indicators

Market Signals
Indicator
VGZ
VTGN
Relative Strength Index (RSI) 62.79 55.48
Support Level $2.06 $0.22
Resistance Level $2.66 $0.32
Average True Range (ATR) 0.12 0.04
MACD 0.03 0.01
Stochastic Oscillator 70.73 20.16

Price Performance

Historical Comparison
VGZ
VTGN

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: